The study tests the combination of capivasertib, a drug intended to inhibit cancer cell growth, with established treatments like CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) and ...

Dr Hope Rugo explores how evolving endocrine strategies and targeted therapies are enhancing outcomes in hormone ...

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

DelveInsight's“ Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ ...

DelveInsight's,“ Advanced Endometrial Cancer Pipeline Insight 2025” report provides comprehensive insights about 25+ ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Despite significant advances in early detection, surgery, radiotherapy, and systemic treatment of breast cancer, late relapse ...

The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...